长效卡博特韦联合利匹韦林肌注后生殖道和直肠内药物浓度及HIV-1 RNA抑制
CAB与RPV在各腔室分布不同,所有参与者在所有基质中HIV-1 RNA均<20拷贝/mL。
要点
- 换用长效CAB+RPV每2月肌注后,所有参与者各腔室HIV-1 RNA均<20拷贝/mL。
- 游离CAB在精浆、直肠组织及阴道宫颈液中均超过EC50。
- 游离RPV在直肠组织及阴道宫颈液中超过EC50,但在精浆中未超过EC50。
核心结论
- 换用每两个月肌注长效CAB+RPV后第4个月,所有参与者在血浆、精浆、直肠组织及阴道宫颈液中HIV-1 RNA均<20拷贝/mL。
主要发现
- CAB与RPV在各腔室分布不同。
- 游离CAB在精浆、直肠组织及阴道宫颈液中超过EC50。
- 游离RPV在直肠组织及阴道宫颈液中超过EC50,但在精浆中未超过EC50。
- 所有参与者在所有基质中HIV-1 RNA<20拷贝/mL。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study examined cabotegravir (CAB) and rilpivirine (RPV) distribution and HIV suppression in genital and rectal compartments after switching to long-acting intramuscular CAB + RPV administered every two months. At month 4, drug concentrations were measured in blood plasma, seminal plasma (SP), rectal tissue (RT), and cervicovaginal fluid (CVF). Thirty-one participants (16 cisgender men, 15 cisgender women) were included. CAB and RPV exhibited different distributions between compartments. Unbound CAB exceeded the EC50 in SP, RT and CVF while unbound RPV exceeded the EC50 in RT and CVF but not in SP. All participants maintained HIV-1 RNA <20 copies/mL in all matrices. Clinical Trial Registration: EudraCT Number: 2021-006779-41.
引用
- Fernández A, Scévola S, Niubó J, et al. Cabotegravir and Rilpivirine Concentrations and HIV-1 RNA Suppression in Genital Fluids and Rectum in People with HIV on Long-Acting Intramuscular Cabotegravir Plus Rilpivirine Antiretroviral Therapy. J Infect Dis. 2026. PMID: 41172282. doi:10.1093/infdis/jiaf551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。